NCT00278252

Etoposide in Treating Young Patients With Relapsed Ependymoma

Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (estimated)
• Sponsor: Children's Cancer and Leukaemia Group · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well etoposide works in treating young patients with ependymoma.

Detailed description

OBJECTIVES: Primary * Determine the response rate in young patients with relapsing and/or refractory ependymoma treated with a rapid schedule of intravenous etoposide. Secondary * Determine the possibility of second surgery or additional radiotherapy in these patients. OUTLINE: This is a multicenter study. Patients receive etoposide IV over 1 hour on days 1-3, 8-10, and 15-17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients whose tumor becomes resectable after courses 3 or 6 undergo surgical resection. After completion of study treatment, patients are followed periodically for approximately 5 years. PROJECTED ACCRUAL: At least 14 patients will be accrued for this study.

Conditions

• Brain and Central Nervous System Tumors

Interventions

Type	Name	Description
DRUG	etoposide
PROCEDURE	conventional surgery

Timeline

• Start date: 2001-07-01
• Primary completion: 2010-07-01
• First posted: 2006-01-18
• Last updated: 2013-08-07

Locations

1 site across 1 country: United Kingdom